Glaxo Group Limited

Peter Clark

Michael D Dowle

Brian Evans

Compounds are disclosed of formula (I): ##STR1## wherein one of R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-6 alkyl C.sub.3-6 alkenyl, hydroxy, C.sub.1-4 alkoxy or a C.sub.2-5 alkoxycarbonyl group, a phenyl or substituted phenyl group or a phen(C.sub.1-4)alkyl or substituted phen(C.sub.1-4)alkyl group; and the other two each independently represents hydrogen, C.sub.1-6 alkyl, or R.sup.2 and R.sup.3 together form an alkylene chain --(CH.sub.2).sub.n --where n is 2 or 3, bridging the nitrogen atoms to which they are attached; R.sup.4 and R.sup.5, each independently represents hydrogen, C.sub.1-3 alkyl or propenyl; R.sup.6 represents hydrogen, C.sub.1-3 alkyl, and the physiologically acceptable salts and solvates thereof. The compounds (I) have potent and selective vasoconstrictor activity and are potentially useful for the treatment of migraine. The compounds (I) may be formulated in conventional manner as pharmaceutical compositions for administration by any convenient route.

Growing community of inventors

Edmonton, Canada

Peter Clark